These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 12469657)
21. Impediments to clinical research in the United States. Kramer JM; Smith PB; Califf RM Clin Pharmacol Ther; 2012 Mar; 91(3):535-41. PubMed ID: 22318614 [TBL] [Abstract][Full Text] [Related]
22. Governance of clinical research. Camilleri M; Tremaine WJ Am J Gastroenterol; 2012 Mar; 107(3):336-8. PubMed ID: 22388015 [TBL] [Abstract][Full Text] [Related]
23. Cancer research and clinical trial in action: an important exercise before you embark on your study. Carbone L; Kurtzman SH; Leong SP Cancer Treat Res; 2007; 132():291-309. PubMed ID: 17305029 [No Abstract] [Full Text] [Related]
24. The basics of human subjects protection. Yoder LH Medsurg Nurs; 2006 Apr; 15(2):95-8; quiz 99. PubMed ID: 16700248 [No Abstract] [Full Text] [Related]
26. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]
27. The Office of Human Research Protections. Chamberlain B Clin Nurse Spec; 2008; 22(6):268. PubMed ID: 18955842 [No Abstract] [Full Text] [Related]
28. Strengthening the regulation of clinical trials and bioresearch monitoring. FDA Consum; 2006; 40(6):35. PubMed ID: 17333566 [TBL] [Abstract][Full Text] [Related]
29. Reporting problems in human research and resultant investigations by IRBs. Maloney DM Hum Res Rep; 2002 Aug; 17(8):6-7. PubMed ID: 12731495 [No Abstract] [Full Text] [Related]
30. Citation for a discussion of noncompliance. Lab Anim (NY); 2011 Feb; 40(2):35. PubMed ID: 21252973 [No Abstract] [Full Text] [Related]
31. Protection of research subjects. Pesando JM N Engl J Med; 2003 Jul; 349(2):188-92; author reply 188-92. PubMed ID: 12856655 [No Abstract] [Full Text] [Related]
32. Expanding disclosure of conflicts of interest: the views of stakeholders. Brody BA; Anderson C; McCrary SV; McCullough L; Morgan R; Wray N IRB; 2003; 25(1):1-8. PubMed ID: 12833897 [No Abstract] [Full Text] [Related]
33. Citation for a discussion of noncompliance. A word from OLAW and USDA. Brown P; Gipson C Lab Anim (NY); 2011 Feb; 40(2):36. PubMed ID: 21252974 [No Abstract] [Full Text] [Related]
34. Gaining approval for clinical research. Cobb V; Srinivasan N; Lambiase P Br J Hosp Med (Lond); 2016 Jul; 77(7):414-8. PubMed ID: 27388381 [TBL] [Abstract][Full Text] [Related]
35. FDA scrutiny and pediatric clinical investigations. Kadzielski MA; Gordon JH Cost Qual; 2001 Jun; ():33-6. PubMed ID: 11482257 [No Abstract] [Full Text] [Related]
36. When informed consent is not required in studies. Maloney DM Hum Res Rep; 2006 Jun; 21(6):3. PubMed ID: 17111532 [No Abstract] [Full Text] [Related]
37. Clinical trials face heightened scrutiny as science and commerce appear to merge. Lorman AJ J Biolaw Bus; 2001; 4(4):23-32. PubMed ID: 12751494 [TBL] [Abstract][Full Text] [Related]
38. From 'Designated Member' back to 'Full Committee'? A word from OLAW and USDA. Brown P; Gipson C Lab Anim (NY); 2011 Jan; 40(1):12. PubMed ID: 21173767 [No Abstract] [Full Text] [Related]
39. Administrative Actions for Noncompliance; Lesser Administrative Actions. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2016 Apr; 81(64):19033-6. PubMed ID: 27044118 [TBL] [Abstract][Full Text] [Related]
40. Institutional review boards and medical devices. Less JR; Alpert S; Nightingale SL JAMA; 1994 Sep; 272(12):968-9. PubMed ID: 8084066 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]